FDA Approves New Oral Treatment for Treatment-Resistant Herpes Lesions in Immunocompromised Patients
Federal regulators have granted approval for a novel oral medication designed to address stubborn and persistent herpes simplex virus (HSV) infections in vulnerable populations. Announced by MedPage Today, the Food and Drug Administration (FDA) approved pritelivir, marketed under the brand name Hovilpri, as a targeted therapeutic option for individuals battling treatment-refractory mucocutaneous lesions caused by HSV-1 and HSV-2.
This approval specifically targets immunocompromised patients who have not found success with conventional antiviral therapies. According to the reporting, herpes simplex virus infections are incurable and frequently manifest as painful sores around the lips, nostrils, eyes, and genital regions. For people with suppressed immune systems—such as those undergoing treatments for cancer, living with HIV, or managing organ transplants—these outbreaks can become severe, chronic, and difficult to manage with standard medications.
How the New Medication Works
Pritelivir functions differently than older generations of antiviral medications. It belongs to a class of medications known as helicase-primase inhibitors. This mechanism of action allows the drug to effectively combat strains of HSV that have developed resistance to standard nucleoside analogue therapies, such as acyclovir, valacyclovir, and famciclovir, as well as foscarnet-based interventions.
In statements reported by MedPage Today, Dr. Cynthia Wat, chief medical officer for drug manufacturer AICuris, emphasized the critical nature of these therapeutic developments. Dr. Wat noted that for patients dealing with treatment-refractory infections, achieving rapid healing of lesions while preserving overall tolerability remains an essential priority in clinical management.
Clinical Trial Findings and Efficacy
The regulatory approval was heavily supported by data gathered from the open-label, phase III PRIOH-1 clinical trial. This study evaluated the safety and efficacy of once-daily pritelivir tablets against investigators’ choice of alternative treatments, which included foscarnet, cidofovir, or imiquimod. The trial enrolled 101 immunocompromised participants experiencing mucocutaneous HSV infections that had failed to respond to previous therapies like acyclovir, valacyclovir, or famciclovir.
The study population encompassed a wide array of underlying clinical conditions contributing to immunosuppression. Participants included individuals with hematologic malignancies and disorders, patients who had undergone hematopoietic stem-cell or solid-organ transplantation, people living with HIV, individuals managing autoimmune or inflammatory diseases, and those facing nonhematologic malignancies.
The primary efficacy endpoint of the trial focused on complete lesion healing by day 28 of the regimen. The findings demonstrated a notable clinical advantage for the new drug:
- 63% of patients treated with a 100-milligram daily dose of pritelivir achieved complete healing of all lesions by day 28.
- 34% of patients receiving the investigators’ choice of alternative treatments reached the same endpoint within the same timeframe.
Regarding safety and side effects, clinical observations indicated that the most frequent adverse reaction reported among individuals receiving pritelivir was headache. Health authorities and medical professionals continue to monitor patients utilizing specialized therapies to ensure ongoing tolerability and safety.
As medical landscapes evolve for complex infectious diseases, the introduction of helicase-primase inhibitors offers a much-needed therapeutic avenue for populations facing heightened vulnerabilities due to compromised immune systems.
Source: MedPage Today
